LUNG CANCER MARKET 2018 COVERS VITAL PLAYERS AS: PFIZER, MERCK, F. HOFFMANN-LA ROCHE AG, NOVARTIS, BRISTOL-MYERS SQUIBB, SANOFI, ETC

This MRFR Market Perspective Examines the Historical Trends and Current Scenario of the “Global Lung Cancer Market” to Deliver a Highly Pertinent Growth Forecast. The Report Includes Key Trends, Drivers And Restraints That Are Likely To Influence The Market Over The Next Five Years.

Lung Cancer Market – Scenario

Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, and fatigue and chest pain. The two types of lung cancers are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).

The NSCLC type accounts for almost 80% of the total lung cancers. The cure rates for the two types of lung cancers exchange their positions with the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage four. The global market of Lung Cancer is expected to reach USD 36929.8 million in 2023 from USD 15219.7 million in 2016 with a CAGR of 13.5% during the forecast period 2017-2023.

Almost 85% of cases of lung cancer are due to long-term tobacco smoking. Cigarette smoke contains at least 73 known carcinogens. Other factors causing lung cancer are genetic factors and exposure to triggers and carcinogens such as radon gas, asbestos, radioactive materials, second-hand smoke, or air pollution. It has also been demonstrated that passive smokers have a 20–30% increase in risk.

Download PDF Sample of this Report @ https://www.marketresearchfuture.com/sample_request/1185

The treatments for lung cancer include surgery, chemotherapy, and radiotherapy with NSCLC responding better to surgery and SCLC usually responding better to chemotherapy and radiotherapy. Notably, smoking is the primary driver for the rising cases of lung cancer. According to World Health Organization (WHO) tobacco kills more than 7 million people each year of which more than 6 million deaths are the result of direct tobacco use. Lung cancer is the leader with a whopping 37% of deaths. Of more concern is the rising rates of lung cancer due to passive smoking.

Prominent Players:

Pfizer

ELI Lilly and Company

Merck & Co.

F. Hoffmann-La Roche AG

Novartis

Bristol-Myers Squibb

Sanofi and others.

Regional Analysis of Global Lung Cancer Market:

The global lung cancer market has been segmented by region comprises of North America, Europe, Asia Pacific and Middle East & Africa. North America leads the world owing to better healthcare, high income and excellent reimbursement. North America is followed by Europe and is expected to reach USD 8,536.3 million by the end of forecast period of 2023.

Asia Pacific is expected to be the fastest growth market and is expected to be led by China, India and South Korea. The Middle East and Africa market is expected demonstrate moderate growth and will be led by the gulf economies.

Market Dynamics of Global Lung Cancer Market:

Segments for Global Lung Cancer Market:
Types - SCLC and NSCLC
Treatments - Surgery, Chemotherapy, Radiotherapy, Photodynamic therapy (PDT) and Laser therapy
End users - Hospitals & Clinics, Cancer Research Centers and Laboratories
Lung Cancer Market - Competitive Analysis

The lung cancer market is currently dominated by various players. Lung cancer has become one of the nost common causes of cancer death worldwide. So, in recent years various existing and new marketers are continuously coming up with innovative products to control this condition.

For instance, F. Hoffmann-La Roche Ltd, a Switzerland based company, manufactures various cancer treatment products such as anti-bcl-2 (SP66) Rabbit Monoclonal Primary Antibody, anti-c-MYC (Y69) Rabbit Monoclonal Primary Antibody, anti-CD7 (SP94) Rabbit Monoclonal Primary Antibody, anti-CEA (TF 3H8-1) Primary Antibody, anti-Cytokeratin 5/6 (D5/16B4) Mouse Monoclonal Primary Antibody, anti-E-cadherin (EP700Y) Rabbit Monoclonal Primary Antibody, and others. In the year 2013, Roche received FDA approval for Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer.

Major TOC of Lung Cancer Market Research Report - Global Forecast to 2023:

1 Report Prologue

2 Introduction

3 Research Methodology

4 Porters Five Forces

5 Market Dynamics

6 Global Lung Cancer Market By Types

7 Global Lung cancer Market By Treatments

8 Global Lung Cancer Market by End Users

9 Global Lung Cancer Market by Regions

10 Company Landscape

11 Company Profiles

Read full report@ https://www.marketresearchfuture.com/reports/lung-cancer-market-1185

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com